Key result
Adjusted-dose warfarin reduces stroke risk by approximately 70% in patients with nonvalvular atrial fibrillation, while aspirin provides a modest 20% risk reduction.
Why the study?
Does antithrombotic therapy (warfarin or aspirin) reduce the risk of ischemic stroke in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Antithrombotic therapy vs Alternative antithrombotic therapy or no treatment
Design
Review
Authors
Loading...
May inform antithrombotic decisions in nonvalvular AF; leaves open comparative effectiveness versus contemporary agents.
Does antithrombotic therapy (warfarin or aspirin) reduce the risk of ischemic stroke in patients with nonvalvular atrial fibrillation?
Effect estimate: 70% risk reduction
Warfarin is highly efficacious for stroke prevention in high-risk patients with nonvalvular AF, while aspirin provides modest benefit and may be indicated for low-risk patients.
Hart et al. (1998) conducted a review in Nonvalvular atrial fibrillation. Adjusted-dose warfarin vs. Aspirin was evaluated on Ischemic stroke (70% risk reduction). Adjusted-dose warfarin reduces stroke risk by approximately 70% in patients with nonvalvular atrial fibrillation, while aspirin provides a modest 20% risk reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: